Psychopharmacological Drugs Advisory Committee

February 14, 2001

Briefing Information

NDA 21-253: Zyprexa® (olanzapine IM, Eli Lilly, Inc.)

Eli Lilly and Company

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Information

Addendum

Food and Drug Administration

Overview

Review and Evaluation of Clinical Data

Statistical Review and Evaluation